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Abstract
Until recently, only bovine-derived thrombin was available for use as a stand-alone topical hemostat
or as a component of other hemostatic devices. Concerns over a number of case reports of
immune-mediated coagulopathies associated with the use of bovine-derived thrombin resulted in
a United States Food and Drug Administration warning letter being issued in 1996 and the later
addition of a boxed warning ("Black Box Warning") to all bovine-derived thrombin products. Since
2007, both a human-pooled plasma thrombin product and a recombinant thrombin have entered
the market.
With the addition of these two products to the topical thrombin class, a unique situation has
developed in which only a single member (bovine-derived thrombin) within the class carries the
Food and Drug Administration's strongest cautionary language about possible adverse events
related to an agent's use. Neither the human-pooled plasma thrombin nor the recombinant
thrombin products have a boxed warning; although, the human-pooled plasma product does
include a precaution/warning about infectious agent transmission - a warning common to products
derived from human sources. This report will address this unique situation and the impact, clinical
and non-clinical, that thrombin choice may have. Since alternatives are now available, institutions
may need to revisit their formulary choice of thrombin preparation, taking into consideration the
potential risks associated with bovine-derived products.
Findings
Annually, between 370,000 and 500,000 patients in the
United States are exposed to topical bovine thrombin
(bThrombin) for surgical hemostasis [1]. Thrombin is a
clotting factor, the main role of which is to convert solu-
ble fibrinogen into insoluble strands of fibrin, the founda-
tion of a blood clot [2]. Since thrombin's first clinical
applications in the 1940s, its ease of use and utility in gen-
eral, cardiovascular, orthopedic, gynecologic, and neuro-
logic surgical procedures, either as standalone agent or in
combination with surgical sponges, has become a main-
stay in surgical hemostasis. Beginning in the 1950s, how-
ever, cases of immune reactions due to bThrombin
exposure have continued to appear in the literature. In
1990, the first description of bThrombin antibodies with
cross-reactivity to native coagulation factors was reported,
ultimately resulting in an FDA warning letter regarding
occasional hemostatic abnormalities and finally, the
inclusion of a boxed warning in the package insert of
bThrombin [2].
To date, over 100 cases of bThrombin-associated acquired
factor V and thrombin (factor IIa) antibodies have been
reported in the literature and have been associated with
various adverse events. [2] A search of PubMed and
Medline databases for English-language reviews and case
reports has demonstrated that new cases of immune-
mediated coagulopathies (IMC) have continued to
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emerge since 2001 [1,3-6]. Given the inconsistent report-
ing of involved agents, confounding diagnoses, and a low
index of suspicion in the medical field, the number of
affected patients may be under-reported to a significant
degree [7]. These antibodies may be associated with
potentially serious, and in rare instances, fatal hemostatic
abnormalities, and clinicians need to be aware that these
coagulopathies may result from the use of bThrombin.
The manifestations of bThrombin-associated IMC can
range from abnormal coagulation studies without clinical
sequelae to hemorrhagic immune-mediated coagulopa-
thies requiring reoperation. The intent of this short report
is to increase awareness of the unique nature of the topical
thrombin class as it pertains to the immunogenic profiles
of the agents in the class, and to briefly describe clinical
and non-clinical aspects of thrombin choices.
Thrombin from bovine sources is the oldest of its class
(Thrombin-JMI, GenTrac, Inc, Middleton, WI) and is
derived through a conversion reaction in which bovine
prothrombin is activated by tissue thromboplastin in the
presence of calcium chloride. The resulting product is
then chromatographically purified and undergoes ultrafil-
tration to reduce factor V and its fragments [8]. Two new
products have recently been approved and were devel-
oped to address concerns centering on the immunogenic-
ity of the bThrombin product. The first to become
available in 2007 was a human-plasma-derived thrombin
product (pdThrombin) (Evithrom, OMRIX biopharma-
ceuticals, Kiryat Ono, Israel); followed in early 2008 by
the first recombinant human thrombin product
(rhThrombin) to be approved by the United States Food
and Drug Administration (FDA) (Recothrom, ZymoGe-
netics, Inc., Seattle, WA).
PdThrombin is derived from pooled plasma obtained
from FDA-licensed plasmapheresis centers and is antigen-
ically distinct from bovine thrombin in both amino acid
sequence and glycosylation patterns [2]. RhThrombin is
produced by Chinese hamster ovary (CHO) cells from
precursor recombinant prethrombin-1 derived from cell
culture and has an identical amino acid sequence and
disulfide-bonding pattern to human thrombin derived
from plasma. In separate phase 3, comparative clinical tri-
als, rhThrombin versus bThrombin and pdthrombin ver-
sus bThrombin found the newest agents equal in efficacy
to bThrombin with a similar adverse event profiles [9,10].
Both products did, however, demonstrate a statistically
significant lower incidence of anti-product antibody for-
mation compared to bovine thrombin. In the only study
of its type to date, rhThrombin was found to be minimally
immunogenic in patients with preexisting antibodies to
bThrombin products and the authors concluded that
rhThrombin could be used safely in patients with or with-
out preexisting antibovine product antibodies [11].
Recent studies have demonstrated that the current ultrafil-
tration methods for bThrombin appear to remove signifi-
cant amounts of bovine factor V as well as other antigens
and viruses [12]. These manufacturing changes were
designed to remove immunogenic contaminants that are
believed to be at least as immunogenic as the bThrombin
itself [8,12]. However, this still represents only a reduc-
tion in factor V contamination, not complete removal,
and the clinical significance of this ongoing contamina-
tion is unknown. (The remote possibility still exists that
anti-factor V antibodies may be generated following the
use of bThrombin and the black box warning remains
[13]).
A recent paper by Singla et al in the Journal of the Ameri-
can College of Surgeons demonstrated that 15.6% of
patients with documented or likely exposure to
bThrombin were positive for anti-bovine thrombin anti-
bodies up to 3 years post-exposure [11]. This finding is
significant because patients treated with older formula-
tions may remain at risk for developing IMC if re-exposed
to bThrombin for several years after their initial exposure.
It bears repeating that the warning on bThrombin is
explicit about not re-exposing patients to b-thrombin if
they have antibodies to bThrombin. Unfortunately, there
is no commercially available test for detecting these anti-
bodies.
Additionally, should an IMC develop, an average hospital
stay may increase in duration by a factor of 2 to 2.5 if a
transfusion is required [14]. Institutions and clinicians
should be aware of the potential for use of large quantities
of already scarce resources such as blood and blood prod-
ucts, not to mention the time, discomfort, and cost of
serial laboratory testing, as well as the risks of transfusion-
related complications. Other costs that may or may not be
reported include those resulting from imaging studies that
may be repeated serially to determine the need for surgical
intervention to achieve hemostasis, and reoperation.
Repeat operations carry their own inherent risks and con-
sequences to patients and institutions, since many times
the costs are unrecoverable. Furthermore, in the current
environment, reimbursements for adverse events are
steadily being reduced, or in some cases eliminated
entirely, for events and outcomes that are judged to be
avoidable or preventable [15].
The unique circumstance of only a single member of the
thrombin class bearing a warning of potentially serious
adverse events resulting from its use may have more far-
reaching implications. The Code of Federal Regulations Title
42 Section 482.25 (42CFR § 482.25) states that "...The
medical staff is responsible for developing policies and proce-
dures that minimize drug errors. This function may be dele-
gated to the hospital's organized pharmaceutical service..." AsPublish with BioMed Central    and   every 
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a result, regulators in some states have created an addi-
tional expectation that drugs with black box warnings
may require additional processes and systems prior to dis-
pensing and utilization in order to minimize risks dis-
cussed in the warning. This is not to imply that black box
warnings or lack of direct data prohibit the use of sound
clinical judgment in prescribing. Experience, careful con-
sideration, and sound reasoning form the basis for deci-
sions. However, careful consideration must include the
recognition of all aspects of an agent's profile, including
the black box warnings advising caution and care.
Conclusion
While the safety profile of bThrombin has generally been
good, there are numerous case studies in the literature
describing clinically significant defects in hemostasis, sec-
ondary to the formation of antibodies to coagulation pro-
teins. Prior to 2007, there were no commercial
alternatives to bovine-derived thrombin, but two new
thrombin products have come on the market,
pdThrombin and rhThrombin, neither of which carries
the black box warning and, in the case of rhThrombin,
appear to be safe to use in patients previously exposed to
bThrombin. In this class, formulary decisions should be
driven by considerations such as the potential costs of
managing an acquired, bovine-associated, immune-medi-
ated coagulopathy should one develop, including the cost
of blood, immunosuppressants, and other therapeutics
along with the costs of an extended hospital stay.
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